

DRUG NAME: Ipilimumab

SYNONYM(S): MDX-010¹; BMS-734016¹

COMMON TRADE NAME(S): YERVOY®

CLASSIFICATION: immunotherapy

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

MECHANISM OF ACTION:

Ipilimumab is a recombinant, fully human monoclonal antibody that binds to and blocks human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Blocking CTLA-4 results in T-cell activation, proliferation, and lymphocyte infiltration into organ tissues and tumours, which leads to tumour cell death. Ipilimumab is an immune-potentiator and can cause inflammatory adverse reactions resulting from increased or excessive immune activity related to its mechanism of action.²

PHARMACOKINETICS:

Distribution	confined primarily to the extracellular fluid volume (consistent with its large molecular weight); steady state achieved by fourth dose	
	cross blood brain barrier?	ipilimumab is not believed to cross the blood brain barrier due to its molecular size; however, activated T-cells can ³ and ipilimumab shows activity against brain mets ³⁻⁵
	volume of distribution ^{6,7}	7.21 L; increases with increasing body weight
	plasma protein binding	no information found
Metabolism	not metabolized by cytochrome p450 or other drug metabolizing enzymes	
	active metabolite(s)	no information found
	inactive metabolite(s)	no information found
Excretion	systemic clearance increases with increasing body weight ⁷	
	urine	no information found
	feces	no information found
	terminal half life ^{2,6,7}	14.7-15.6 days
	clearance ⁶	15.3 mL/h
Elderly	no reported differences in safety or efficacy	

Adapted from standard reference² unless specified otherwise.

USES:

Primary uses:

- *Colorectal cancer
- *Lung cancer, non-small cell
- *Melanoma
- *Mesothelioma
- *Renal cell cancer

Other uses:

*Health Canada approved indication

SPECIAL PRECAUTIONS:

Contraindications:

- patients with active, life-threatening autoimmune disease or with organ transplantation graft where further immune activation is potentially imminently life-threatening²

Caution:

- ipilimumab can cause severe and fatal **immune-mediated** adverse reactions, including enterocolitis, intestinal perforation, hepatitis, dermatitis, neuropathy, endocrinopathy, etc.; onset usually occurs during the induction period, but may occur months after last dose.²
- **systemic immunosuppressants** or corticosteroids may interfere with the pharmacodynamic activity of ipilimumab: therefore, except for the treatment of immune-mediated adverse reactions, systemic immunosuppressants or corticosteroids should be avoided during ipilimumab treatment.²
- the safety and efficacy of **vaccination** in patients receiving immunotherapy is currently being investigated⁸⁻¹¹

Carcinogenicity: not formally studied; however, no hyperplastic, preneoplastic, or neoplastic lesions were reported in peripheral blood or lymphoid tissues in monkeys in long-term toxicology studies using immunostimulatory doses of ipilimumab.¹²

Mutagenicity: not formally studied; however, it is not expected that ipilimumab (as a large recombinant protein) would interact directly with DNA or other chromosomal materials.¹²

Fertility: not formally studied. In toxicity studies, no histopathologic changes in sperm or ovum morphology in the study animals were attributed to ipilimumab. Decreased testicular weights were reported in monkeys, but no other changes in reproductive or endocrine organ weights or drug-related microscopic changes were reported in male or female study animals. Ipilimumab bound specifically to connective tissue in monkey ovary; however, similar binding to human ovary was not observed.¹²

Pregnancy: Human IgG1 is known to cross the placental barrier. Therefore, based on its mechanism, ipilimumab has the potential to be transmitted from mother to fetus and cause harm to the developing fetus. In animal reproductive studies, abortion, stillbirth, premature delivery, low birth weight, and infant mortality were reported with higher incidence in a dose-related manner, starting in the third trimester. Developmental external or visceral abnormalities in the urogenital system were identified in some subjects exposed in utero. For female patients of reproductive potential, contraception is recommended during treatment with ipilimumab and for 3 months after treatment has ended.¹²

Breastfeeding is not recommended due to the potential secretion into breast milk. Human IgG is known to be secreted in human breast milk, therefore, there is potential for ipilimumab to be passed from mother to nursing child.²

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important^{13,14}.

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
blood and lymphatic system/ febrile neutropenia	anemia (2-12%, severe 3%) ^{2,15}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <i>bold, italics</i>	
endocrine	adrenal insufficiency (2%)
	hyperthyroidism (2%)
	hypothyroidism (2%)
	hypophysitis (2%, severe 2%) ¹⁵
	hypopituitarism (2-4%, severe 2-3%) ^{2,15}
eye	blurred vision (2%)
	uveitis (2%)
gastrointestinal	<i>emetogenic potential: low</i> ¹⁶
	abdominal pain (11-15%, severe 2%) ^{2,15}
	colitis (8%, severe 5%) ^{2,15}
	constipation (2-21%, severe 2%) ^{2,15}
	<i>diarrhea</i> (27-33%, severe 5%) ^{2,15}
	<i>enterocolitis</i> (35%, severe 7%); sometimes fatal
	gastrointestinal hemorrhage (2%)
	gastrointestinal perforation (<1%)
	gastroesophageal reflux disease (<1%)
	nausea (23-35%, severe 2%) ^{2,15}
	vomiting (12-24%, severe 2%) ^{2,15}
general disorders and administration site conditions	<i>extravasation hazard: none</i> ¹⁷
	asthenia (5%, severe 2%)
	chills (5%)
	edema (4%, severe <1%)
	<i>fatigue</i> (24-42%, severe 5-7%) ^{2,15}
	injection site reactions (4%)
	pain (2%)
	pyrexia (8-12%) ^{2,15}
hepatobiliary	hepatitis (1%) ¹⁵
immune system (see paragraphs following Side Effects table)	any <i>immune-mediated reaction</i> (15-61%, severe 15%) ^{2,15}
	dermatologic (44%, severe 2%) ^{2,15}
	endocrinopathy (4-8%, severe 4%) ^{2,15}
	gastrointestinal (29%, severe 8%) ¹⁵
	hepatotoxicity (1-4%) ^{6,15}
	infusion reaction (2-6%; severe <1%) ^{2,18}
	neuropathy (<1%)
	pulmonary sarcoid-like granulomatosis ¹⁹ (<1%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <i>bold, italics</i>	
investigations	ALT increase (2%)
	AST increase (1%)
	serum corticotrophin decrease (2%, severe 1%) ^{2,15}
	serum thyrotropin increase (1%) ¹⁵
	weight decrease (3%)
metabolism and nutrition	appetite decrease (11-27%, severe 2%) ^{2,15}
	dehydration (2%)
musculoskeletal and connective tissue	arthralgia (4%, severe <1%)
	musculoskeletal pain (5%)
	myalgia (4%)
neoplasms	tumour pain (2%)
nervous system	dizziness (1%)
	headache (5-15%, severe 2%) ^{2,15}
renal and urinary	renal failure (2%, severe <1%)
respiratory, thoracic and mediastinal	cough (3-16%) ^{2,15}
	dyspnea (2-15%, severe 4%) ^{2,15}
skin and subcutaneous tissue (see paragraph following Side Effects table)	alopecia (2%)
	erythema (5%)
	night sweats (2%)
	<i>pruritus</i> (24-26%) ^{2,15}
	<i>rash</i> (19-26%, severe 1%) ^{2,15} ; predominantly maculopapular, can be intensely pruritic ¹
	Stevens-Johnson syndrome (<1%) ¹
	toxic epidermal necrolysis (<1%) ¹
	vitiligo (2-11%) ^{1,2,15} ; may be irreversible ²⁰
vascular	flushing (5%)
	hypotension (3%, severe 2%)

Adapted from standard reference² unless specified otherwise.

Immune-mediated adverse reactions, sometimes fatal, can involve any organ system. The gastrointestinal tract, liver, skin, endocrine, and nervous systems are most commonly involved. Signs and symptoms suggestive of immune-related reactions may be nonspecific. **Diarrhea, increased stool frequency, bloody stool, liver enzyme test elevations, rash, and endocrinopathies** must be considered immune-mediated. Most reactions occur during the induction phase, however onset months after the last dose has also been reported. Early diagnosis and appropriate management are necessary to minimize life-threatening complications. Patients should be strongly advised not to self-treat any of these symptoms and the importance of reporting any worsening of symptoms should be emphasized. Due to the mechanism of the inflammatory reactions observed, management of severe reactions requires systemic high-dose corticosteroids with or without additional immunosuppressive therapy. Permanently discontinue ipilimumab for severe immune-mediated adverse reactions.² For further information on management of

immune-mediated adverse reactions, see BC Cancer Protocol SCIMMUNE [Management of Immune-Mediated Adverse Reactions to Checkpoint Inhibitors Immunotherapy](#).

Immune-mediated **dermatitis**, including Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations has been reported. Signs of dermatitis should be considered immune-mediated, unless an alternate etiology is identified. The median time to onset of moderate, severe, or life-threatening dermatitis is three weeks, but has ranged up to more than 17 weeks from the initiation of ipilimumab. The median number of doses received prior to onset is two. Withhold ipilimumab for moderate to severe symptoms. Permanently discontinue ipilimumab for Stevens-Johnson syndrome, toxic epidermal necrolysis, or complicated rash, and administer systemic corticosteroids. When dermatitis is controlled, corticosteroid tapering may be initiated and continued over at least one month. Mild to moderate dermatitis, such as localized rash and pruritus, may be treated symptomatically. Administer topical or systemic corticosteroids for symptoms which do not improve within one week.^{1,2} Vitiligo may manifest as discrete scattered macules or widespread generalized patches of depigmentation and tends to be irreversible, even after ipilimumab is discontinued.²⁰ There is no known treatment for ipilimumab-induced vitiligo; prevention of sunburn in depigmented areas is important.²¹ Sun avoidance and/or broad-spectrum sunscreen is recommended prophylactically for dermatologic toxicities.^{22,23}

Immune-mediated **endocrinopathies**, some requiring hospitalization or urgent medical intervention, have been reported, including hypopituitarism, adrenal insufficiency, hypogonadism, and hypothyroidism. Median time to onset of moderate to severe endocrinopathy is 11 weeks, ranging to over 19 weeks after initiation of ipilimumab. The median number of doses prior to onset is four. Monitor for clinical signs of hypophysitis, adrenal insufficiency (including adrenal crisis), and hyper- or hypothyroidism. Patients may present with fatigue, headache, mental status changes, abdominal pain, unusual bowel habits, and hypotension, or other non-specific symptoms resembling brain metastases or underlying disease. Thyroid function tests and clinical chemistries should be monitored prior to each treatment. Withhold ipilimumab in symptomatic patients, and initiate systemic corticosteroids and appropriate hormone replacement.^{1,2}

Immune mediated **enterocolitis** can be severe or life-threatening; fatalities have been reported. Median time to onset is 6-8 weeks after initiation of treatment, and the median number of doses administered prior to onset is three. Monitor for diarrhea, abdominal pain, mucous or blood in stool, and the signs of bowel perforation. Fever may be present. Rule out infectious etiologies in symptomatic patients, and conduct further investigations for persistent or severe symptoms. For moderate enterocolitis, withhold ipilimumab and administer anti-diarrheal treatment. Systemic corticosteroids may be initiated for symptoms persisting beyond one week. For severe enterocolitis, ipilimumab should be permanently discontinued and systemic corticosteroids initiated. Upon improvement to grade 1 or less, corticosteroid tapering may be initiated, and then continued over at least one month. Rapid corticosteroid tapering may result in recurrence or worsening of symptoms. Patients with inadequate response to corticosteroids may also require immunosuppressive therapy. Infliximab has been used.²

Severe or life-threatening **hepatotoxicity** has been reported, including in some instances, immune-mediated hepatitis. Hepatotoxicity is manifested by elevations of AST or ALT at least 2.5 times the upper limit of normal or total bilirubin at least 1.5 times the upper limit of normal. Fatalities have been reported. Monitor liver function (AST, ALT, and bilirubin) and assess for hepatotoxicity prior to each treatment. Rule out infectious and malignant etiologies in patients with hepatotoxicity. Withhold ipilimumab for grade 2 hepatotoxicity. For grade 3 or higher hepatotoxicity, permanently discontinue ipilimumab and administer high dose corticosteroids. After sustained improvement or tests return to baseline, corticosteroid tapering may be initiated and continued over one month. Mycophenolate has been used for patients with persistent severe hepatitis despite high-dose corticosteroids.²

Immune-mediated **neuropathies**, such as **Guillain-Barré syndrome**, **myasthenia gravis**, and **peripheral motor neuropathy**, some fatal, have been reported. Monitor for symptoms of motor or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, or paresthesia. Withhold ipilimumab for moderate neuropathy not interfering with daily activities. For severe neuropathy interfering with daily activities, ipilimumab should be permanently discontinued. Systemic corticosteroids may be required.²

INTERACTIONS: none known²

SUPPLY AND STORAGE:

Injection: Bristol-Myers Squibb Canada supplies ipilimumab as an aqueous solution in 50 mg and 200 mg preservative-free, single-use vials in a concentration of 5 mg/mL. Refrigerate. Protect from light.²

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Additional information:

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in **bold, italics**

Subcutaneous	no information found
Intramuscular	no information found
Direct intravenous	do NOT use ²⁴
Intermittent infusion ^{12,25-30}	over 30 min; administer using a 0.2 or 1.2 micron in-line filter
Continuous infusion	no information found
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BC Cancer usual dose noted in **bold, italics**

<i>Intravenous:</i>	Cycle Length:	
	3 weeks ^{15,24,31-33} :	3 mg/kg IV for one dose on day 1 (total dose per cycle 3 mg/kg)
	3 weeks ^{24,29} :	1 mg/kg IV for one dose on day 1 (total dose per cycle 1 mg/kg)

BC Cancer usual dose noted in ***bold, italics***

Cycle Length:
6 weeks^{24,26,30}: ***1 mg/kg IV for one dose on day 1***
(total dose per cycle 1 mg/kg)

<i>Concurrent radiation:</i>	no information found
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated
<i>Dosage in renal failure</i> ²⁴ :	mild to moderate impairment: no dose adjustment required severe impairment: no information found
<i>Dosage in hepatic failure</i> ²⁴ :	mild impairment: no dose adjustment required moderate to severe impairment: no information found
<i>Dosage in dialysis:</i>	no information found

Children: no information found

REFERENCES:

1. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012;30(21):2691-2697
2. Bristol Myers Squibb Canada. YERVOY® product monograph. Montreal, Quebec; 1 February . 2012
3. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol* 2012;13:459-465
4. Maio M, Testori A, Ascierto PA, et al. The NIBIT-M1 trial: activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. *J Clin Oncol* 2012;30(Supplement):ASCO meeting abstract 8529
5. Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. *J Clin Oncol* 2010;28(15s):ASCO meeting abstract 8523
6. Bristol-Myers Squibb. YERVOY® prescribing information. Princeton, NJ; March 2011
7. Culver ME, Gatesman ML, Mancl EE, et al. Ipilimumab: a novel treatment for metastatic melanoma. *Ann Pharmacother* 2011;45:510-519
8. Brest P, Mograbi B, Hofman P, et al. COVID-19 vaccination and cancer immunotherapy: should they stick together? *Br J Cancer* 2022;126(1):1-3
9. Chong C, Park VJ, Cohen B, et al. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. *Clin Infect Dis* 2020;70(2):193-199
10. Desage A, Bouleffour W, Rivoirard R, et al. Vaccination and immune checkpoint inhibitors: does vaccination increase the risk of immune-related adverse events? A systematic review of literature. *Am J Clin Oncol* 2021;44(3):109-113
11. Oosting SF, van der Veldt, A. A. M., GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. *Lancet Oncol* 2021;22(12):1681-1691
12. Bristol-Myers Squibb Canada Co. YERVOY® Product Monograph. Montreal, Quebec; November 24 2022
13. Kate Yoo. BC Cancer Agency Skin/Melanoma Tumour Group Pharmacist. Personal communication. 3 October 2012
14. Richard Klasa MD. BC Cancer Agency Skin/Melanoma Tumour Group. Personal communication. 31 October 2012
15. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363(8):711-723
16. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012
17. BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 February 2012
18. Momtaz P, Park V, Panageas KS, et al. Safety of infusing ipilimumab over 30 minutes. *J Clin Oncol* 2015;33(online ahead of print):1-1901

19. Berthod G, Lazor R, Letovanec I, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. *J Clin Oncol* 2012;30(17):e156-e159
20. Choi JM. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. *Semin Cutan Med Surg* 2014;33:40-48
21. Choi JM. How to recognize and manage ipilimumab-induced dermatologic adverse events. *The ASCO Post* 2013;4(16)
22. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. *Clinical Medicine Insights: Oncology* 2012;6:53-66
23. Scarpati GDV, Fusciello C, Perri F, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. *OncoTargets and Therapy* 2014;4(7):203-209
24. Bristol-Myers Squibb Canada Co. YERVOY® Product Monograph. Montreal, Quebec; March 3 2022
25. BC Cancer Lung Tumour Group. (LUAVPCIPNI) BC Cancer Protocol Summary for First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin, Ipilimumab and Nivolumab. Vancouver, British Columbia: BC Cancer; June 7 2022
26. BC Cancer Lung Tumour Group. (LUAVPPIPI) BC Cancer Protocol Summary for First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab. Vancouver, British Columbia: BC Cancer; June 7 2022
27. BC Cancer Skin and Melanoma Group. (SMAVFIPI) BC Cancer Protocol Summary for the First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab. Vancouver, British Columbia: BC Cancer; February 1 2023
28. BC Cancer Skin and Melanoma Group. (SMAVALIPNI) BC Cancer Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma using Alternative Dosing Regimen of Ipilimumab and Nivolumab. Vancouver, British Columbia: BC Cancer; February 1 2023
29. BC Cancer Genitourinary Tumour Group. (GUAVIPNI) BC Cancer Protocol Summary for the Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Ipilimumab and Nivolumab. Vancouver, British Columbia: BC Cancer; September 1 2022
30. BC Cancer Lung Tumour Group. (LUMMIPNI) BC Cancer Protocol Summary for the Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab. Vancouver, British Columbia: BC Cancer; October 1 2022
31. BC Cancer Skin and Melanoma Tumour Group. (SMAVFIPI) BC Cancer Protocol Summary for the First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab. Vancouver, British Columbia: BC Cancer; January 1 2022
32. BC Cancer Skin and Melanoma Tumour Group. (SMAVIPI) BC Cancer Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab. Vancouver, British Columbia: BC Cancer; January 1 2022
33. BC Cancer Skin and Melanoma Tumour Group. (SMAVIPNI) BC Cancer Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab. Vancouver, British Columbia: BC Cancer; May 1 2022